viewSensyne Health PLC

Sensyne Health PLC - Price Monitoring Extension

RNS Number : 6174F
Sensyne Health PLC
17 November 2020

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: Sensyne Health PLC

Price: 157.5

Market: AIM
Market Cap: £250.56 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sensyne Health launch first digital health product in the U.S for diabetes...

Sensyne Health's CEO (LON:SENS) Lord Paul Drayson talks to Proactive London about their first digital health product in the U.S that can remotely monitor for diabetes in pregnancy. The group's partner Cognizant will oversee the roll-out of GDm-Health across the Atlantic. Drayson talks...

on 15/12/20